Medopad and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into a strategic partnership to validate, scale and potentially commercialise the ReVeRe platform as a novel digital biomarker for Alzheimer’s disease (AD). Johnson & Johnson Innovation Limited facilitated the deal.
The ReVeRe platform, developed and clinically validated by Janssen Pharmaceuticals, Inc., aims to enable reliable, remote and automated assessment and monitoring of verbal memory in individuals at risk of AD.
ReVeRe automates, on an iPad platform, the administration and scoring of Rey Auditory Verbal Learning Test (RAVLT) – along with other tests of attention and executive function known to be relevant in early stages of AD.
With its experience in implementing and scaling digital healthcare solutions across the National Health Service (NHS) and other international health systems, Medopad will allow the ReVeRe technology to be deployed across patient populations in both the UK and China.
The goal of this collaboration is to implement a home-based, validated automated cognitive tool that could facilitate unsupervised and reliable longitudinal assessment of early cognitive decline due to AD within a real-world environment.
“Once we have concluded implementation and final testing, we aim to be able to screen an entire nation for Alzheimer’s disease at low cost,” said Dan Vahdat, Medopad CEO and Founder.
The number of people with dementia doubles every 20 years, with the total number set to reach 75 million in 2030. At present there is a lack of methodology to diagnose patients at scale and to understand the disease progression.